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Abstract
Sensory gating deficit in schizophrenia patients has been well-documented. However, a central conceptual issue,
regarding whether the gating deficit results from an abnormal initial response (S1) or difficulty in attenuating the
response to the repeating stimulus (S2), raise doubts about the validity and utility of the S2/S1 ratio as a measure of
sensory gating. This meta-analysis study, therefore, sought to determine the consistency and relative magnitude of the
effect of the two essential components (S1 and S2) and the ratio. The results of weighted random effects meta-analysis
revealed that the overall effect sizes for the S1 amplitude, S2 amplitude, and P50 S2/S1 ratio were  0.19 (small), 0.65
(medium to large), and 0.93 (large), respectively. These results confirm that the S2/S1 ratio and the repeating (S2)
stimulus differ robustly between schizophrenia patients and healthy controls in contrast to the consistent but smaller
effect size for the S1 amplitude. These findings are more likely to reflect defective inhibition of repeating redundant
input rather than an abnormal response to novel stimuli.
Descriptors: Sensory gating, Schizophrenia, P50, Gating out
Deficits in both the early pre-attentive stage and later evaluative
processes of information processing are well-documented in
schizophrenia patients (e.g., Turetsky, Bilker, Siegel, Kohler, &
Gur, 2009). The putative mechanism underlying these deficits is
the inability to inhibit irrelevant or redundant information inflow
(Venables, 1964). This inhibitory control, or gating of neuronal
responses to afferent information, is believed to be essential for
sustaining attention in a changing environment and for appro-
priate responses to afferent stimuli (Hubel &Wiesel, 1959). It has
been argued that the sensory gating problem may result from
neuronal hyper-excitability due to a flaw in neuronal inhibitory
pathways of cortical and sub-cortical areas (Adler et al., 1982;
Flach et al., 1996; Freedman, Waldo, Bickford-Wimer, & Naga-
moto, 1991).
To study this sensory gating mechanism, an auditory P50
conditioning (S1)-testing (S2) paradigm is often used while re-
cording the electroencephalogram (EEG) (Adler et al., 1982;
Freedman et al., 1987, 1991). In this paired stimulus paradigm
(PSP), two identical auditory stimuli are presented as pairs (500
ms apart between clicks or sounds) with an inter-trial interval
(ITI) of 8 to 10 s between the pairs (e.g., Freedman et al., 1987;
Zouridakis & Boutros, 1992). The P50 mid-latency auditory
evoked response (MLAER) attained from the PSP is the most
positive peak approximately 40–90 ms after the onset of auditory
stimuli (e.g., Boutros, Korzyukov, Jansen, Feingold, & Bell,
2004). The degree of sensory gating, denoted as T/C ratio or S2/
S1 ratio, is determined by the ratio of the amplitude of the P50
response to the testing click (Tor S2) to the amplitude of the P50
response to the conditioning click (C or S1; e.g., Freedman et al.,
1987). In healthy individuals, the S2 amplitude is usually dimin-
ished by over 60% of the S1 amplitude (Moxon, Gerhardt,
Gulinello, & Adler, 2003). In schizophrenia patients, however,
the amount or percent of the S2 amplitude decrement over the S1
amplitude has not been clearly documented.
Despite the publication of three meta-analyses supporting the
presence of P50 sensory gating deficit in schizophrenia patients
(Bramon, Rabe-Hesketh, Sham, Murray, & Frangou, 2004; de
Wilde, Bour, Dingemans, Koelman, & Linszen, 2007a; Patter-
son et al., 2008), there are methodological and conceptual con-
cerns regarding the use of the T/C or S2/S1 ratio. These concerns
include the low noise to signal ratio (SNR), the low test–retest
reliability in healthy controls (Fuerst, Gallinat, & Boutros, 2007;
Rentzsch, Jockers-Scherübl, Boutros, & Gallinat, 2008; Smith,
Boutros, & Schwarzkopf, 1994), and the lack of blinding during
data collection in some studies (Boutros, 2008). Other method-
ological concerns, such as use of antipsychotic medication and
illness duration, were not found to be important in the three prior
meta-analyses (Bramon et al., 2004; de Wilde et al., 2007a; Pat-
terson et al., 2008). Both de Wilde et al. (2007a) and Patterson et
al. (2008) proposed specific recommendations for future sensory
gating research to address methodological issues (see de Wilde
et al., 2007a; Patterson et al., 2008 for details). However, none of
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these meta-analyses have addressed conceptual issues of sensory
gating.
The central conceptual factor is the relativemagnitude of both
the responses to S1 and S2 stimuli to the noted decreased de-
crement of the response to S2 stimuli in schizophrenia patients as
compared to the decrement of S2 responses recorded from
healthy control subjects. This decrement is most commonly as-
sessed by dividing the amplitude of the responses to S2 by the
amplitudes of the responses to S1. Although the S2/S1 ratio is
most widely used to assess gating, the S1-S2 mathematical dif-
ference has also been used (Smith et al., 1994). The more widely
employed ratio is taken as an operational measure of the brain’s
habituation or gating capacity. An elevated ratio is taken to de-
note decreased brain ability to habituate or suppress irrelevant or
redundant incoming sensory input (Freedman et al., 1987). An
elevated ratio can result from an abnormally low response to S1
stimuli, or a decreased attenuation of the S2 response. The
physiological implications of the two scenarios are different and
significantly impact the understanding of the physiological de-
viations (Boutros et al., 2009). We have previously proposed that
two physiological aberrations, abnormally low S1 responses and
abnormally decreased ability to suppress S2 responses, are dem-
onstrated in schizophrenia patients and that these two abnor-
malities may or may not be completely independent (Boutros et
al., 2009). We propose that, on a fundamental level, if there is no
gating abnormality, the ratio should remain low no matter how
small the response to S1 is, unless there is a yet unidentified floor
effect. Similarly, if a gating deficit exists, the amplitude decre-
ment from S1 to S2 should remain small no matter how large the
response to S1 is.
Stemming from earlier work (Jansen, Hegde, & Boutros,
2004) and more recent work (Turetsky et al., 2009), this issue is
critical to the P50 gating literature. For instance, both Blum-
enfeld and Clementz (2001) and Jansen et al. (2004) asserted that
a decreased S1 amplitude in schizophrenia patients is the major
determinant of the elevated P50 S2/S1 ratio noted in these in-
dividuals. Moreover, Johannesen et al. (2005) noticed an abnor-
mally small S1 response in the presence of a normal S2 response
leading to a high P50 S2/S1 ratio among schizophrenia patients,
and their findings are further supported by a recent study (i.e.,
Brenner et al., 2009).
Studies questioning the relative importance of the S1 ampli-
tudes, however, indicate that poor sensory gating, i.e., high P50
S2/S1 ratio, is not associated with the S1 amplitude (Clementz,
Geyer, & Braff, 1997; Jin et al., 1997). Also, Freedman et al.
(1987) indicated that poor sensory gating is a result of a lack of
gating out the redundant S2 stimuli. Thus, a significant dis-
agreement exists regarding whether the P50 S2/S1 ratio is the
result of a defective response to S1 stimuli or a hitherto uniden-
tified interaction between the S1 and S2 responses in both
schizophrenia patients and healthy subjects (e.g., Blumenfeld &
Clementz, 2001; Boutros & Belger, 1999; Clementz et al., 1997;
Jin et al., 1997; Johannesen et al., 2005).
It is thus fundamental for future sensory gating research uti-
lizing the PSP to establish whether the paradigm examines the
habituation process (i.e., the degree of decrement from S1 to S2)
or that the decrement noted is simply a reflection of the abnormal
response to S1 stimuli. A consistently stronger association of S1
values compared to that of S2 and the S2/S1 ratios would sup-
port the latter possibility and throw serious doubt regarding the
implications of the PSP abnormalities reported in association
with schizophrenia. Therefore, the purpose of this meta-analysis




The literature search began with three published meta-analyses
of sensory gating in schizophrenia patients and healthy controls
(i.e., Bramon et al., 2004; de Wilde et al., 2007a; Patterson et al.,
2008). The Bramon et al. (2004) study searched sensory gating
papers published between January 1994 and August 2003 in the
databases MEDLINE and SCIENCE CITATION INDEX
using the keywords: P50 AND [Psychosis OR Schizophrenia].
They also carried out a search for papers published between
January and August 2003 in several journals and included 20
studies in their analysis. The de Wilde et al. (2007a) study used
the keywords P50 and schizophrenia to conduct a search for
papers published between 1982 and October 2006 in the da-
tabases MEDLINE, PUBMED, and Science Direct, and
crossed-referenced citations. They included 34 studies in their
analysis. The Patterson et al. (2008) study reviewed studies pub-
lished between 1982 and 2006 as found in PUBMED. They
included 39 studies in their analyses. Across these three meta-
analyses, 52 studies were included.
For our meta-analysis, we started with these 52 studies and
added 18 studies published between January 2007 andDecember
2009 found in the databases MEDLINE, PUBMED, and Sci-
ence Direct using the keywords P50 sensory gating and schizo-
phrenia. Thus, there was the potential for 70 studies to be
analyzed before subsequent review for inclusion.
Inclusion Criteria
As some studies did not include sufficient information for anal-
ysis, we established a priori the following inclusion criteria: (1)
report separately the number of participants in each of the
schizophrenia and healthy control groups, (2) report separately
the mean and standard deviation (SD) of the S1 and S2 P50
amplitudes in each of the schizophrenia and healthy control
groups, and (3) report separately the mean and SD of P50 S2/S1
ratio in each of the schizophrenia and healthy control groups. If
studies reported P50 amplitudes and ratios in plots or graphed
the findings only, they were not included in the analysis.
After carefully reviewing the articles based on these inclusion
criteria, 35 articles (publications) were included in this meta-
analysis with a total number of 58 different comparisons between
schizophrenia patients and healthy controls. The 58 different
comparisons were obtained as some of the articles includedmore
than one schizophrenia patient group. Among these 35 articles,
four had been included in all three previously published meta-
analyses, nine were included in at least two meta-analyses, and
four were in only one previously published meta-analysis. Thus,
18 out of the 35 included articles were not included in any of the
three previous meta-analyses.
Data Collected
Prior to analysis, reported standard errors of mean were con-
verted to standard deviations. Reported P50 suppression rates
were converted to the S2/S1 ratio by subtracting the S2 percent
reduction from 100% and dividing by 100. Thus, a 35% reduc-
tion in S2 would convert to a 0.65 ratio.
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Meta-Analysis Procedure and Data Analysis
Consistent with the three meta-analysis studies of P50 sensory
gating in schizophrenia patients (i.e., Bramon et al., 2004; de
Wilde et al., 2007a; Patterson et al., 2008), the effect sizes for the
means of the S1 amplitude, S2 amplitude, and S2/S1 ratio were
calculated using Cohen’s d, or the difference between themean of
control group and the mean of schizophrenia group divided by
the pooled standard deviation. In addition, random effects meta-
analysis was used, consistent with two of the previous studies
(Bramon et al., 2004; Patterson et al., 2008). The random effects
meta-analysis assumes that true effect size has normal distribu-
tion from a population of studies investigated and provides an
overall mean estimation of effect size and its confidence interval.
Although the fixed effect analysis was conducted and used the
inverse variance method of weighting, only the results of the
random effects models are present. The models were weighted
using the DerSimonian-Laird method (DerSimonian & Laird,
1986).
As suggested by de Wilde et al. (2007a), we calculated the
overlap statistic (OL%) to examine the overlap in the P50 mea-
sure distribution between schizophrenia patients and healthy
controls. When d is zero, there is 100% overlap between the two
groups. If d is one, it equates to 44.6% overlap (Zakzanis, 2001).
Publication bias was examined by calculating the number of un-
published studies, or Nfs (Orwin, 1983), needed to obtain a small
effect size (Cohen, 1988), and by examining funnel plots. Ho-
mogeneity was tested using the Q statistic, with the magnitude of
homogeneity quantified with I2. Effect size calculations were
conducted usingMIX Pro 2.0 software (BiostatXL.com) and the
OL%was calculated using Excel software (Microsoft), a spread-
sheet designed by DeCoster and Iselin (Stat-Help.com).
Results
Table 1 presents the means of the reported P50 S2/S1 ratios and
amplitudes for both schizophrenia patients and healthy controls
from the 35 articles (58 comparisons). For healthy controls, the
mean S1 amplitude ranged from 0.79 mVto 5.93 mV, themean S2
amplitude ranged from 0.18 mVto 2.89 mV, and themean P50 S2/
S1 ratio ranged from 0.16 to 0.94. Among the schizophrenia
patients, themean S1 amplitude ranged from 1.40 mVto 6.39 mV,
the mean S2 amplitude ranged from 0.80 mV to 3.73 mV, and the
mean P50 S2/S1 ratio ranged from 0.32 to 1.42. Among the 58
comparisons, schizophrenia patients had a smaller mean S1 am-
plitude than controls in 38 comparisons (65.52%). For the S2,
schizophrenia patients had a larger mean S2 amplitude than
controls in 52 out of 58 comparisons (89.66%). For the S2/S1
ratio, schizophrenia patients had a largermean ratio than healthy
controls in 56 comparisons (96.55%).
Figure 1a, 1b, and 1c present the forest plots of the effect size
for the S1 amplitude, S2 amplitudes, and S2/S1 ratio, respec-
tively. Each square is located at the estimate of the effect size with
the size of the square proportional to the sample size. The blue
horizontal lines indicate the 95% confidence interval of the effect
size for each comparison. The red line indicates the estimated
effect size with its corresponding prediction interval. Table 2
presents the effect sizes of the S1 amplitude, S2 amplitude, and
P50 S2/S1 ratio for 58 comparisons between schizophrenia pa-
tients and healthy controls. The effect size for the S1 amplitude
from the random effects model was  0.19 with the standard
error of 0.049 and the 95% confidence interval of  0.29 to
 0.10. The OL statistic ranged from 38.78% to 100%
(mean5 76.83%  15.72%). For the combined effect size, the
OL statistic showed that there was 85.74% overlap in the mean
S1 amplitude between schizophrenia patients and healthy con-
trols. There was an indication of heterogeneity in the S1 ampli-
tude across the studies, Cochrane Q5 116.69, po.0005,
I2 5 51.15%. The Orwin’s Nfs for publication bias showed that
there were no additional studies needed to support the null hy-
pothesis of at least a small effect size (d5 0.2) as the combined
effect size was small; the funnel plot of the S1 amplitude (see
Figure 2) supported the lack of publication bias due to a sym-
metrical distribution.
For the S2 amplitude, the effect size in each comparison
ranged from  0.42 to 4.53. The effect size for the S2 amplitude
from the random effects model was 0.65 with the standard error
of 0.084 and the 95% confidence interval of 0.48 to 0.81. The OL
statistic ranged from 1.18% to 100% (mean5 63.59% 
24.30%). For the combined effect size, the OL statistics showed
that therewas 59.62%overlap in themean S2 amplitude between
schizophrenia patients and healthy controls. There was also an
indication of heterogeneity, Cochrane Q5 344.61 po.0005,
I2 5 83.46%. The Orwin’s Nfs indicated that 131 studies were
necessary to reduce the combined effect size of the S2 amplitude
to a small effect size. The funnel plot of the S2 amplitude (see
Figure 3) did not suggest a publication bias.
For the P50 S2/S1 ratio, the effect size in each comparison
ranged from  0.29 to 3.97. The effect size from the random
effects model was 0.93 with the standard error of 0.088 and a
95% confidence interval of 0.75 to 1.10. The OL statistics
showed an overlap of 2.42% to 98.28% with the mean of
51.44%  23.63%, indicating a 47.37% overlap in the P50
S2/S1 ratio between schizophrenia patients and healthy controls.
There was also a lack of homogeneity across the 58 comparisons
among the 35 articles, Cochrane Q5 368.74, po.0005,
I2 5 84.54%. The funnel plot of the S2/S1 ratio (see Figure 4)
displayed a clear asymmetric pattern, suggesting a publication
bias against findings of small or absent effects.
Examination of Heterogeneity in S1 Amplitude, S2 Amplitude,
and P50 S2/S1 Ratio
To investigate possible sources for the heterogeneity of the S1
amplitude, S2 amplitude, and P50 S2/S1 ratio between schizo-
phrenia patients and healthy controls, we stratified the compar-
ison by research groups (assessing the impact of different
protocols, such as Colorado group, as was done in two of the
three prior meta-analyses: deWilde et al., 2007a; Patterson et al.,
2008) and limited the analysis to one comparison from each
publication. In addition, we investigated whether use of blinding
to diagnostic group when measuring P50 amplitude or type of
medication for the patients with schizophrenia were potential
sources for the heterogeneity. As the research group and blinding
were the only moderators to have a more than 10% effect on the
effect sizes, Table 3 presents the results of the effect sizes (the
same random effects weighted procedure), Cochrane Q, and I2
for the S2/S1 ratio and the S1 and S2 amplitudes for these mod-
erators. The results showed that larger values of the effect sizes
were obtained from the Colorado group than those from other
research groups. However, regardless of the research group, the
effect size for S1 amplitude was smaller than that for S2 ampli-
tude or for the P50 S2/S1 ratio.
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Table 1. Means (Standard Deviations) of Both S1 and S2 Amplitudes (in mV) and P50 S2/S1 Ratios for Both Schizophrenia Patients and
Healthy Controls in Each Study
Study Number of subjects in data analysis S1 amplitude S2 amplitude S2/S1 ratio
Adler et al. (2004) 177 healthy controls 3.00  1.50 0.60  0.07 0.198  0.210
132 schizophrenia patients (all) 2.40  1.80 1.70  1.70 0.789  0.646
88 schizophrenia patients (atypical antipsychotic) 2.20  1.40 1.40  1.20 0.704  0.537
34 schizophrenia patients (typical antipsychotic) 2.70  2.60 2.30  2.70 1.1101  0.879
10 schizophrenia patients (no medication) 3.10  1.70 2.10  1.40 0.741  0.278
Arnfred et al. (2003) 22 healthy controls 2.52  1.39 1.01  0.84 0.40  0.30
12 schizophrenia patients 2.56  1.63 0.89  0.71 0.32  0.24
Becker et al. (2004) 25 healthy controls 5.44  2.72 2.23  1.78 0.44  0.27
25 schizophrenia patients (atypical antipsychotic) 6.39  3.96 3.73  4.18 0.57  0.41
25 schizophrenia patients (typical antipsychotic) 4.34  2.70 2.94  1.41 0.82  0.45
Boutros et al. (1991) 13 healthy controls 5.93  3.08 2.89  1.39 0.52  0.15
13 paranoid schizophrenia patients (typical antipsychotic) 4.05  2.30 2.37  1.60 0.59  0.22
13 undifferentiated schizophrenia patients (typical antipsychotic) 2.93  1.92 2.91  1.09 1.26  0.71
Boutros and Belger (1999) 12 healthy controls 3.30  2.10 1.00  0.08 0.51  0.44
12 schizophrenia patients (typical antipsychotic) 2.50  1.80 3.30  1.90 1.42  0.58
Boutros et al. (2004) 23 healthy controls 2.60  2.30 1.30  1.40 0.54  0.38
23 schizophrenia patients (atypical antipsychotic) 2.60  1.60 2.00  1.90 0.80  0.69
Boutros et al. (2009) 31 healthy controlsFMean of all days base-to-peak measure 3.10  2.20 1.20  1.20 0.41  0.33
35 schizophrenia patients (atypical antipsychotic)FMean of all days
base-to-peak measure
2.30  2.40 1.80  2.60 0.79  0.53
36 healthy controlsFMean of all days peak-to-peak measure (for
T/C ratio: 35 healthy controls)
2.80  2.50 1.40  1.50 0.67  0.60
35 schizophrenia patients (atypical antipsychotic)FMean of all days
peak-to-peak measure
2.90  2.70 2.00  2.00 0.79  0.65
Brenner et al. (2009) 19 healthy controls 4.62  2.58 0.94  0.89 0.94  2.54
18 schizophrenia patients (medicated) 4.28  2.46 2.35  2.11 0.73  0.71
Brockhaus-Dumke, Mueller
et al. (2008a)
32 healthy controls 3.90  2.25 1.83  1.44 0.4019  0.3862
32 schizophrenia patients 3.46  2.63 1.75  1.41 0.6877  0.5613
Brockhaus-Dumke,
Schultz-Lutter et al. (2008b)
41 healthy controls (for S2 amplitude and T/C ratio: 35 healthy
controls)
3.12  1.50 1.44  1.06 0.43  0.28
14 chronic schizophrenia patients (for S2 amplitude: 13 chronic
schizophrenia patients; for T/C ratio: 12 chronic schizophrenia
patients)
2.00  0.84 1.89  1.39 0.85  0.42
29 schizophrenia patients (antipsychotic-naive) (for S2 amplitude and
T/C ratio: 21 schizophrenia patients)
3.14  1.75 1.96  1.32 0.65  0.38
Clementz et al. (1998a) 36 healthy controls 4.23  1.33 0.95  1.01 0.231  0.222
36 schizophrenia patients (28 medicated; 8 unmedicated) 3.50  1.26 1.99  1.23 0.612  0.465
Clementz et al. (1998b) 45 healthy controls 4.16  1.20 1.21  0.97 0.299  0.228
44 schizophrenia patients (medicated) 3.35  1.14 1.88  0.92 0.594  0.316
Clementz and Blumenfeld
(2001)
20 healthy controls 2.30  0.80 0.80  0.50 0.38  0.24
20 schizophrenia patients (14 atypical, 6 typical antipsychotic) 1.80  0.80 0.80  0.50 0.48  0.27
Devrim-Üçok et al. (2008) 24 healthy controls 3.89  2.00 1.97  1.34 0.59  0.44
16 acute schizophrenia patients (medicated) 2.91  2.37 2.33  1.24 0.96  0.58
16 post-acute schizophrenia patients (medicated) 3.08  1.52 1.47  0.96 0.60  0.49
de Wilde et al. (2007b) 28 healthy controls 2.02  1.20 0.93  1.01 0.4313  0.3822
27 healthy siblings of schizophrenia patients 2.18  1.44 0.82  0.77 0.4164  0.4215
53 inpatient schizophrenia patients (medicated) 2.05  1.41 1.11  1.05 0.6502  0.5582
Fresán et al. (2007) 17 healthy controls 3.00  2.00 1.00  0.90 0.30  0.10
14 violent schizophrenia patients (unmedicated) 3.80  2.00 2.90  1.70 1.00  0.80
18 nonviolent schizophrenia patients (unmedicated) 2.70  2.00 1.70  1.20 1.00  1.30
Ghisolfi et al. (2004) 24 healthy controls 5.40  2.94 2.00  0.98 0.444  0.235
12 schizophrenia patients 4.10  1.73 3.20  1.04 0.883  0.436
Ghisolfi et al. (2006) 28 healthy controls 5.60  2.90 2.10  1.10 0.454  0.209
28 schizophrenia patients (medicated) 5.20  3.10 3.30  1.80 0.792  0.373
Guterman and Josiassen
(1994)
10 healthy controls 5.51  3.18 1.75  1.28 0.37  0.28
10 schizophrenia patients 4.93  4.02 2.81  2.05 1.25  2.26
Hong et al. (2004) 16 healthy controls 3.00  1.60 1.10  0.90 0.39  0.34
23 schizophrenia patients (medicated) 3.30  2.20 1.80  1.10 0.65  0.39
Hong et al. (2008) 70 healthy controls 4.04  3.10 2.01  1.67 0.56  0.33
74 healthy relatives of schizophrenia patients 3.31  2.75 2.01  2.41 0.60  0.34
102 schizophrenia patients (medicated) 3.91  3.53 2.32  2.83 0.62  0.30
Hong et al. (2009) 62 healthy controls 2.50  1.47 1.45  1.18 0.4122  0.3382
65 schizophrenia patients (baseline) 2.27  1.34 1.95  1.12 0.9419  0.6131
65 schizophrenia patients (atypical antipsychotic after baseline) 2.04  1.13 1.64  1.07 0.8481  0.5538
Jin et al. (1997) 10 healthy controls 5.60  2.97 2.19  1.80 0.37  0.20
10 schizophrenia patients (medication-free for 5 days) 3.34  1.74 2.34  1.74 0.73  0.35
Johannesen et al. (2005) 38 healthy controls 2.14  0.64 1.19  0.65 0.5757  0.3314
37 schizophrenia patients (all; medicated) 1.87  0.54 1.25  0.56 0.6899  0.3081
11 nonparanoid schizophrenia patients (medicated) 1.99  0.44 1.36  0.42 0.6873  0.1868
26 paranoid schizophrenia patients (medicated) 1.83  0.57 1.20  0.61 0.6910  0.3503
Kathmann and Engel (1990) 22 healthy controls 3.00  1.41 2.10  0.94 0.73  0.39
18 schizophrenia patients (medicated) 2.60  0.85 2.10  1.70 0.947  0.82
Kisley et al. (2003) 10 healthy controls, non-REM 1.51  0.62 0.67  0.81 0.39  0.35
10 healthy controls, REM 0.79  0.29 0.18  0.18 0.20  0.22
Discussion
This meta-analysis specifically addresses the relative importance
of measuring S2 amplitude and the ratio measure of sensory
gating compared to only measuring S1 amplitude in people with
schizophrenia. This meta-analysis builds upon previously pub-
lished meta-analyses by investigating the differences in the P50
amplitudes and gating ratios between schizophrenia patients and
healthy controls by including studies published since the publi-
cation of the last meta-analysis (Patterson et al., 2008). The
number of new studies was 18 in just 2 years, underscoring the
significant interest of investigators in the gating function. The
findings clearly show increasing effect size corresponding to ad-
ditional information. The effect size was small for the S1 am-
plitude difference, increased to amedium to large effect size of the
S2 amplitude difference, and finally a large effect size of the S2/S1
ratio between schizophrenia patients and healthy controls.
Together, these findings suggest that sensory gating deficit of
the P50 (S2/S1 ratio) in schizophrenia patients as compared to
healthy controlsmay bemore pertinent to the degree of change in
brain response from S1 to S2 stimuli between healthy controls
and schizophrenia than just measuring the S1 stimuli. However,
although the S2/S1 gating ratio is a dominant measure in the
literature, it may not be the best approach to summarizing sen-
sory gating deficit in schizophrenia, and exploration of different
approaches, such as the S1-S2 amplitude difference, may be
worthwhile.
Our estimates of the effect sizes for S1 amplitude and S2/S1
ratio are remarkably similar to previous meta-analyses (Patter-
son et al., 2008), indicating that, although the number of studies
has increased dramatically and the subtypes of patients have
narrowed, the finding of a larger effect size for S2 amplitude than
that of S1 amplitude appears valid. There is heterogeneity in the
effect size, which is partially related to research groups as
previously shown (Patterson et al., 2008). Unfortunately for
S2/S1 ratio, there appears to be a publication bias with large
negative studies not being submitted or accepted for publication.
Difference in the S1 Amplitude
The mean S1 amplitudes of schizophrenia patients and healthy
controls exhibited awide range of values and a high percentage of
overlapping, yielding a small combined effect size. In 65.52% of
the comparisons, the schizophrenia group had a lower mean S1
amplitude than the control group. These findings were similar to
the previous meta-analysis (Patterson et al., 2008) in which they
rejected zero difference in the S1 amplitude between schizophre-
nia patients and normal controls, but 25 of the 37 studies over-
lapped the zero difference. We thus can conclude that the noted
deficit in habituation or gating of the responses to S2 stimuli
across studies and comparisons is not predicated on a failure to
register the S1 stimuli in schizophrenia patients as the effect size
of S2 amplitude and S2/S1 ratio are much larger. However, this
conclusion is not in line with Jansen et al. (2004) and Brenner et
al. (2009), which proposed that sensory gating deficit in schizo-
phrenia patients is due to the problem in evaluating stimulus in
the sensory encoding and, consequently, a failure in responding
to and detecting the salient information of the S1.
These summary findings across published articles corroborate
the finding at the individual participant level (e.g., Fuerst et al.,
2007). Fuerst et al. (2007) demonstrated that the S1 amplitude
does not correlate with the gating ratio nor significantly predict
the gating ratio in a sample of healthy controls. In addition, data
from schizophrenia patients were in fundamental agreement with
healthy control data (Boutros et al., 2009). Furthermore, this S1
amplitude finding is in line with the results from Jin et al. (1997)
and Clementz et al. (1997). However, whether the P50 S1
amplitude is a candidate for a schizophrenia endophenotype
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Table 1. (Contd.)
Study Number of subjects in data analysis S1 amplitude S2 amplitude S2/S1 ratio
10 schizophrenia patients (medicated), non-REM 1.63  1.27 1.85  2.58 0.93  0.66
10 schizophrenia patients (medicated), REM 1.40  1.02 1.31  1.36 0.93  0.73
Louchart-de la Chapelle et al.
(2005)
88 healthy controls 3.12  2.50 1.17  0.05 0.36  0.20
26 negative symptom schizophrenia patients (atypical antipsychotic) 3.31  2.70 2.48  1.50 0.97  0.60
55 no negative symptom schizophrenia patients (atypical
antipsychotic)
3.60  2.60 2.78  2.20 0.80  0.40
Martin et al. (2007) 108 healthy controls (common gene) 3.10  1.70 0.60  0.70 0.17  0.15
41 healthy controls (variant gene) 2.80  1.30 0.80  0.70 0.34  0.39
26 schizophrenia patients (common gene) 2.10  0.90 1.80  0.90 1.01  0.63
11 schizophrenia patients (variant gene) 2.20  1.50 2.10  1.50 1.11  0.72
Myles-Worsley (2002) 29 healthy controls 2.96  1.59 0.88  0.74 0.307  0.227
29 schizophrenia patients (unmedicated) 1.75  1.40 0.98  0.97 0.716  0.598
56 schizophrenia patients (medicated) 2.04  1.14 1.42  1.14 0.745  0.477
Olincy et al. (2000) 16 healthy controls 2.61  1.57 0.50  0.65 0.1622  0.1210
16 schizophrenia patients 2.53  1.58 1.53  0.85 0.6701  0.1346
Patterson et al. (2000) 10 healthy controls 4.14  2.69 1.71  1.93 0.36  0.25
10 schizophrenia patients 2.57  1.80 2.03  1.64 1.18  1.49
Rentzsch et al. (2007) 18 healthy controls 2.80  1.50 1.10  0.80 0.374  0.179
12 schizophrenia patients without cannabis abuse 3.90  3.10 1.40  0.90 0.366  0.177
15 schizophrenia patients with cannabis abuse 2.80  1.40 1.30  0.70 0.477  0.194
Sánchez-Morla et al. (2008) 63 healthy controls 3.90  2.10 1.70  1.30 0.41  0.23
90 schizophrenia patients 4.40  2.80 2.70  1.90 0.67  0.33
Sánchez-Morla et al. (2009) 64 healthy controls 3.91  2.14 1.68  1.26 0.428  0.255
42 schizophrenia patients (medicated: CLZ) 4.90  2.94 2.75  1.71 0.600  0.258
47 schizophrenia patients (medicated: FGAs) 4.76  2.48 3.07  1.70 0.700  0.332
65 schizophrenia patients (medicated: SGAs) 4.18  2.33 2.59  1.78 0.681  0.375
Yee et al. (1998) 11 healthy controls 3.44  2.38 1.36  0.99 0.38  0.18
22 recent-onset schizophrenia patients (medicated) 3.18  2.26 1.81  1.63 0.59  0.33
remains an open question (Patterson et al., 2008).More research,
thus, is still needed in order to better elucidate the exact contri-
bution of the S1 in the P50 gating process in schizophrenia.
Difference in the S2 AmplitudeF‘‘Gating Out’’
The present study was the first to systematically investigate the
S2 difference between schizophrenia patients and healthy con-
trols, which the previous meta-analyses did not address. In the
current meta-analysis, the medium effect size indicates that the
ability to suppress redundant stimuli is deficient consistently in
schizophrenia patients as compared to healthy controls and
would require fewer patients to detect such a deficiency than
using only S1.
When examining the effect sizes of the S2 amplitude and the
P50 S2/S1 ratio, we speculate that, across studies, the difference
in sensory gating ability between healthy controls and schizo-
phrenia patientsmay possibly be associated with the difference in
brain response to the S2 stimulus, as the effect size of the S2
amplitude was medium to large and the S2/S1 ratio was large.
Based on these effect size results, we further conjecture that, at
the group level, sensory gating deficit in schizophrenia patients
may result from the inability to suppress the S1 response with
S1, S2, and the gating ratio 985
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Figure 1a, 1b, and 1c. Forest plots of effect sizes of the S1 amplitude, S2 amplitude, and S2/S1 ratio from weighted random effects model.
repetition as assessed by measuring the S2 response. However,
this inference needs further investigation with large individual
patient data.
Investigators disagree on the mechanism of the deficient sen-
sory gating. It has been argued that it is due to a neural mal-
function of inhibitory mechanism responsible for ‘‘gating out’’
discarded information (Clementz et al., 1997; Freedman et al.,
1987). It has also been argued that it is a failure of neural mech-
anism responsible for registering salient information (Jansen
et al., 2004). Finally, it has been argued that it is due to an
unusually small S1 response accompanied with an otherwise
typical S2 response (Blumenfeld & Clementz, 2001; Johannesen
et al., 2005). The findings of the current meta-analysis provide
support for the argument that poor sensory gating in schizo-
phrenia patients is a large effect in the published studies and thus
‘‘gating out’’ redundant and irrelevant sensory information.
Difference in the P50 S2/S1 Ratio
The results showed that schizophrenia patients exhibited a larger
S2/S1 ratio than healthy controls and the effect size for the S2/S1
ratio was large, which was consistent with the findings from pre-
vious three meta-analyses (Bramon et al., 2004; de Wilde et al.,
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Figure 1. Continued.
2007a; Patterson et al., 2008). In addition, there was an overlap
in the P50 S2/S1 ratio between healthy controls and schizophre-
nia patients, similar to Patterson et al. (2008), and the range of
the effect size was similar to the previous three meta-analyses.
To investigate the heterogeneity in the P50 S2/S1 ratio, dif-
ferent moderators have been addressed in the previous meta-
analyses (Bramon et al., 2004; deWilde et al., 2007a; Patterson et
al., 2008). For example, Bramon et al. (2004) found that age,
gender, and filter setting could not explain the observed vari-
ability of the effect size in the P50 ratio and suggested that these
parameters contribute similar effects to healthy controls. When
other sources of heterogeneity were examined, studies from one
research group (i.e., Colorado) displayed a larger effect size than
those from other research groups. It is reassuring that the inclu-
sion of 18 more recent studies did not alter this finding, which
remains consistent with that of de Wilde et al. (2007a).
Patterson et al. (2008) suggested that methodological issues,
such as filter settings, click intensity, and blinding the P50 mea-
surement, need to be considered when analyzing P50 S2/S1 ratio
data. When we examined the blinding issue in the S2/S1 ratio,
studies using the blinding procedure revealed a medium to large
effect size, whereas studies with no blinding procedure showed a
S1, S2, and the gating ratio 987
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Adler et al. (2004) 132 schizophrenia patients (all) vs. 177 healthy controls  0.37 0.99 1.31
( 0.60– 0.14) (0.75–1.23) (1.07–1.56)
88 schizophrenia patients (atypical antipsychotic) vs. 177 healthy controls  0.55 1.16 1.44
( 0.81– 0.29) (0.89–1.43) (1.15–1.72)
34 schizophrenia patients (typical antipsychotic) vs. 177 healthy controls  0.18 1.59 2.30
( 0.54–0.19) (1.19–1.99) (1.87–3.24)
10 schizophrenia patients (no medication) vs. 177 healthy controls 0.07 4.53 2.55
( 0.57–0.70) (3.89–5.17) (2.37–2.58)
Arnfred et al. (2003) 12 schizophrenia patients vs. 22 healthy controls 0.03  0.16  0.29
( 0.68–0.73) ( 0.86–0.55) ( 1.00–0.41)
Becker et al. (2004) 25 schizophrenia patients (atypical antipsychotic) vs. 25 healthy controls 0.29 0.48 0.38
( 0.27–0.84) ( 0.09–1.04) ( 0.18–0.94)
25 schizophrenia patients (typical antipsychotic) vs. 25 healthy controls  0.41 0.45 1.05
( 0.97–0.15) ( 0.11–1.01) (0.45–1.64)
Boutros et al. (1991) 13 paranoid schizophrenia patients (typical antipsychotic) vs. 13 healthy  0.69  0.35 0.37
controls ( 1.46–0.08) ( 1.12–0.42) ( 0.40–1.14)
13 undifferentiated schizophrenia patients (typical antipsychotic) vs. 13  1.17 0.02 1.44
healthy controls ( 1.94–0.40) ( 0.75–0.78) (0.67–2.21)
Boutros and Belger
(1999)
12 schizophrenia patients (typical antipsychotic) vs. 12 healthy controls  0.41 1.71 1.77
( 1.21–0.39) (0.91–2.51) (0.97–2.57)
Boutros et al. (2004) 23 schizophrenia patients (atypical antipsychotic) vs. 23 healthy controls 0 0.42 0.47
( 0.58–0.58) ( 0.16–1.00) ( 0.11–1.04)
Boutros et al. (2009) Mean of all days base-to-peak measure:








Mean of all days peak-to-peak measure:








Brenner et al. (2009) 18 schizophrenia patients (medicated) vs. 19 healthy controls ( 0.78–0.51) (0.23–1.58) ( 0.76–0.53)
Brockhaus-Dumke
et al. (2008a)
32 schizophrenia patients vs. 32 healthy controls  0.18  0.06 0.60
( 0.67–0.31) ( 0.54–0.43) (0.10–1.14)
Brockhaus-Dumke
et al. (2008b)
14 chronic schizophrenia patients (for S2 amplitude: 13 chronic schizophrenia patients;
for T/C ratio: 12 chronic schizophrenia patients) vs. 41 healthy controls







29 schizophrenia patients (antipsychotic-naive) (for S2 amplitude and T/C ratio: 21










36 schizophrenia patients (28 medicated; 8 unmedicated) vs. 36 healthy controls  0.70 0.92 1.05
( 1.18– 0.23) (0.46–1.39) (0.58–1.51)
Clementz et al.
(1998b)
44 schizophrenia patients (medicated) vs. 45 healthy controls  0.63 0.71 1.07
( 1.06– 0.21) (0.29–1.12) (0.66–1.49)
Clementz and
Blumenfeld (2001)
20 schizophrenia patients (14 atypical, 6 typical antipsychotic) vs. 20 healthy controls  0.58 0 0.39
( 1.21–0.06) ( 0.62–0.62) ( 0.23–1.01)
Devrim-Üçok et al.
(2008)
16 acute schizophrenia patients (medicated) vs. 24 healthy controls  0.47 0.28 0.76
( 1.11–0.17) ( 0.35–0.92) (0.10–1.41)
16 post-acute schizophrenia patients (medicated) vs. 24 healthy controls  0.46  0.42 0.02
( 1.10–0.19) ( 1.07–0.21) ( 0.61–0.65)
de Wilde et al.
(2007b)
53 inpatient schizophrenia patients (medicated) vs. 28 healthy controls 0.02 0.18 0.44
( 0.44–0.48) ( 0.28–0.63) ( 0.02–0.90)








Fresán et al. (2007) 14 violent schizophrenia patients (unmedicated) vs. 17 healthy controls 0.41 1.49 1.34
( 0.30–1.13) (0.68–2.29) (0.55–2.13)
18 nonviolent schizophrenia patients (unmedicated) vs. 17 healthy controls  0.15 0.68 0.77
( 0.82–0.51) ( 0.01–1.36) (0.08–1.46)
Ghisolfi et al. (2004) 12 schizophrenia patients vs. 24 healthy controls  0.55 0.90 1.27
( 1.08– 0.01) (0.18–1.63) (0.52–2.03)
Ghisolfi et al. (2006) 28 schizophrenia patients (medicated) vs. 28 healthy controls  0.14 1.21 1.28
( 0.83–0.55) (0.64–1.78) (0.70–1.85)
Guterman and
Josiassen (1994)
10 schizophrenia patients vs. 10 healthy controls  0.16 0.65 0.58
( 1.05–0.71) ( 0.25–1.56) ( 0.32–1.47)
Hong et al. (2004) 23 schizophrenia patients (medicated) vs. 16 healthy controls 0.19 0.68 0.70
( 0.45–0.83) (0.05–1.32) (0.06–1.34)
Hong et al. (2008) 102 schizophrenia patients (medicated) vs. 70 healthy controls  0.04 0.13 0.19
( 0.34–0.27) ( 0.18–0.43) ( 0.11–0.50)
102 schizophrenia patients (medicated) vs. 74 healthy relatives of schizophrenic patients 0.19 0.12 0.06
( 0.11–0.49) ( 0.18–0.42) ( 0.24–0.36)
Hong et al. (2009) 65 schizophrenia patients (baseline) vs. 62 healthy controls  0.16 0.43 1.06
( 0.51–0.18) (0.09–0.78) (0.72–1.41)
65 schizophrenia patients (atypical antipsychotic after baseline) vs. 62 healthy controls  0.35 0.17 0.94
( 0.70–0.004) ( 0.18–0.52) (0.60–1.29)
Jin et al. (1997) 10 schizophrenia patients (medication-free for 5 days) vs. 10 healthy controls  0.98 0.09 1.33
( 1.91– 0.05) ( 0.79–0.97) (0.35–2.31)
large effect size. This finding suggests that blinding impacts the
P50 measurement. Whether paying specific attention to methodo-
logical issues, such as strict blinded evaluation of the P50 com-
ponent (Boutros, 2008) and increasing the number of averaged
trials in order to improve the SNR, will impact the overall effect
size of the P50, gating deficit in schizophrenia remains to be seen.
Nonetheless, given the large effect size and the results of mod-
erator analysis consistent with the previous studies, the difference
in the P50 S2/S1 ratio between schizophrenia patients and
healthy controls is plausible, and schizophrenia patients display a
problem in sensory gating compared to healthy controls.
In addition to heterogeneity and methodological issues, our
results indicated a publication bias in P50 S2/S1 ratio, which was
different from both Bramon et al. (2004) and de Wilde et al.
(2007a). This inconsistent finding may be due to the addition of
recent studies since the publication of thosemeta-analyses. There
may now be a bias to expect significant difference in P50 S2/S1
ratio between schizophrenia and controls. Although this publi-
cation bias may be due to our inclusion/exclusion criteria, this is
doubtful as it did not impact our estimates for the S1 amplitude.
Implications for Sensory Gating Research in Schizophrenia
The findings of this present meta-analysis have two major im-
plications for sensory gating research in schizophrenia patients.
First, this study found a small effect size of the S1 amplitude, a
between medium and large effect size of the S2 amplitude, and a
large effect size of the P5 S2/S1 ratio. This finding suggests that a
large effect size of the P50 S2/S1 ratio and S2 amplitude hold
valuable information. In other words, this finding confirms the
supposition that, at the group level, when compared to healthy
controls sensory gating deficit in schizophrenia patients is po-
tentially caused by an augmentation or a lack of reduction in the
S2 response in contrast to healthy controls, suggesting a ‘‘gating
out’’ habituation problem. Our findings suggest that the S2 am-
plitude is necessary to gauge sensory gatingwhen compared to S1
amplitude and that themeasurement of S1 amplitude alone is not
sufficient to predict or assess the difference in gating function
between healthy controls and schizophrenia. Also, the measure-
ment of the S2 amplitude is indispensable to calculate the S1–S2
amplitude difference as another sensory gating index (Smith
et al., 1994; de Wilde et al., 2007a).











37 schizophrenia patients (all; medicated) vs. 38 healthy controls  0.46 0.10 0.36
( 0.92– 0.002) ( 0.35–0.55) ( 0.09–0.82)
11 nonparanoid schizophrenia patients (medicated) vs. 38 healthy controls  0.27 0.30 0.40
( 0.78–0.23) ( 0.20–0.80) ( 0.10–0.91)
26 paranoid schizophrenia patients (medicated) vs. 38 healthy controls  0.51 0.02 0.35
( 1.18–0.17) ( 0.66–0.69 ( 0.32–1.03)
Kathmann and
Engel (1990)
18 schizophrenia patients (medicated) vs. 22 healthy controls  0.34 0 0.36
( 0.97–0.28) ( 0.62–0.62) ( 0.27–0.99)
Kisley et al. (2003) 10 schizophrenia patients (medicated) vs. 10 healthy controls, non-REM 0.13 0.65 1.08
( 0.75–1.00) ( 0.25–1.55) (0.13–2.02)
10 schizophrenia patients (medicated) vs. 10 healthy controls, REM 0.86 1.23 1.43




26 negative symptom schizophrenia patients (atypical antipsychotic) vs. 88 healthy 0.08 1.86 1.84
controls ( 0.36–0.51) (1.36–2.36) (1.34–2.34)
55 no negative symptom schizophrenia patients (atypical antipsychotic) vs. 88 healthy 0.19 1.19 1.51
controls ( 0.15–0.53) (0.83–1.55) (1.13–1.89)
Martin et al. (2007) 26 schizophrenia patients (common gene) vs. 108 healthy controls (common gene)  0.64 1.63 2.77
( 1.07– 0.20) (1.16–2.10) (2.23–3.31)
26 schizophrenia patients (common gene) vs. 41 healthy controls (variant gene)  0.61 1.30 1.37
( 1.11– 0.11) (0.76–1.84) (0.83–1.92)
11 schizophrenia patients (variant gene) vs. 108 healthy controls (common gene)  0.54 1.89 3.72
( 1.16–0.09) (1.22–2.56) (2.94–4.50)
11 schizophrenia patients (variant gene) vs. 41 healthy controls (variant gene)  0.46 1.44 1.65
( 1.13–0.22) (0.72–2.17) (0.91–2.39)
Myles-Worsley
(2002)
29 schizophrenia patients (unmedicated) vs. 29 healthy controls  0.82 0.12 0.92
( 1.36– 0.28) ( 0.40–0.63) (0.38–1.46)
56 schizophrenia patients (medicated) vs. 29 healthy controls  0.71 0.53 1.08
( 1.17– 0.25) (0.08–0.99) (0.60–1.56)
Olincy et al. (2000) 16 schizophrenia patients vs. 16 healthy controls  0.05 1.41 3.97
( 0.75–0.64) (0.63–2.18) (3.28–4.66)
Patterson et al.
(2000)
10 schizophrenia patients vs. 10 healthy controls  0.72 0.19 0.81
( 1.63–0.18) ( 0.69–1.07) ( 0.11–1.72)
Rentzsch et al.
(2007)
12 schizophrenia patients s without cannabis abuse vs. 18 healthy controls 0.50 0.37  0.05
( 0.24–1.24) ( 0.37–1.11) ( 0.78–0.68)
15 schizophrenia patients s with cannabis abuse vs. 18 healthy controls 0 0.27 0.57
( 0.68–0.68) ( 0.42–0.96) ( 0.13–1.27)
Sánchez-Morla
et al. (2008)
90 schizophrenia patients vs. 63 healthy controls 0.20 0.60 0.89
( 0.12–0.52) (0.27–0.93) (0.56–1.23)
Sánchez-Morla
et al. (2009)
42 schizophrenia patients (medicated: CLZ) vs. 64 healthy controls 0.40 .74 0.68
(0.01–0.80) (0.35–1.12) (0.28–1.08)
47 schizophrenia patients (medicated: FGAs) vs. 64 healthy controls 0.37 0.94 0.93
(0.02–0.71) (0.57–1.30) (0.56–1.29)
65 schizophrenia patients (medicated: SGAs) vs. 64 healthy controls 0.12 0.59 0.79
( 0.25–0.50) (0.24–0.913 (0.44–1.13)
Yee et al. (1998) 22 recent-onset schizophrenia patients (medicated) vs. 11 healthy controls  0.12 0.32 0.75
( 0.84–1.29) ( 0.41–1.05) (0–1.49)
The second implication is that the P50 S2/S1 ratio is an op-
erational reflection of the brain’s ability to inhibit redundant
incoming sensory input, a deficiency of which remains a potential
endophenotype for schizophrenia patients. In agreement with
both de Wilde et al. (2007a) and Patterson et al. (2008), several
concerns need to be addressed. Patterson et al. (2008) indicated
that, in order to be an endophenotype, the P50 S2/S1 ratio needs
to be a ‘‘reliable maker that is state-independent and enduring
across different subject characteristics such as diagnostic subtype
and symptom status’’ (p. 243) and questioned the consistency
and specificity of this particular P50measure. In addition, Gould
and Gottesman (2006) list five criteria for an endophenotype.
Largemulticenter studies are necessary to establish the validity of
putative endophenotypes or biomarkers (Olincy et al., 2010).
Limitations and Future Direction
This present meta-analysis has two major limitations. The first
limitation stems from the P50 S2/S1 ratio itself. The P50 S2/S1
ratio has an inherent bias because it is a mathematical index that
the S2 amplitude is divided by the S1 amplitude. As Atchley and
990 W.-P. Chang et al.



































S1 Amplitude Effects Size
–1.50 –1.00 –0.50 0.00 0.50 1.00
Figure 2. Funnel plot to examine publication bias in the S1 amplitude.



























S2 Amplitude Effect Size
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Figure 3. Funnel plot to examine publication bias in the S2 amplitude.
Table 3. Potential Moderators on Estimates of Effect Sizes of S1, S2, and S2/S1 Ratio
Research group Blinding
Colorado group (N5 13) Non-Colorado group (N5 45) Used (N5 17) Not used (N5 41)
S1 amplitude ES  0.39  0.15 0.02  0.32
95% CI  0.56– 0.22  0.26– 0.05  0.10–0.14  0.44– 0.21
SeES 0.087 0.053 0.063 0.057
Q 20.29 81.14 20.66 73.29
p5 .062 p5 .0006 p5 .19 p5 .001
I2 40.86% 45.77% 22.54% 45.43%
S2 amplitude ES 1.39 0.47 0.58 0.71
95% CI 0.95–1.83 0.33–0.61 0.36–0.81 0.48–0.94
SeES 0.225 0.070 0.116 0.117
Q 147.98 141.75 69.05 328.63
po.0001 po.0001 po.0001 po.0001
I2 91.89% 68.96% 76.83% 87.83%
S2/S1 ratio ES 1.93 0.72 0.79 1.08
95% CI 1.48–2.37 0.58–0.86 0.57–1.02 0.82–1.33
SeES 0.228 0.071 0.117 0.130
Q 151.38 146.63 70.63 406.32
po.0001 po.0001 po.0001 po.0001
I2 92.07% 69.99% 77.35% 90.16%
Note: ES5 effect size, 95% CI5 95% confidence interval for effect size, SeES5 standard error of effect size.
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Figure 4. Funnel plot to examine publication bias in the S2/S1 ratio.
his colleagues indicated, when a composite score (i.e., ratio score)
are used from continuous variables, a pronounced spurious cor-
relation occurs between the ratio score and its numerator and
denominator (Atchley, Gaskins, & Anderson, 1976). In addi-
tion, Atchley et al. (1976) noticed that the size of the denom-
inator coefficient of variation contributes to the strength of the
spurious correlation. Due to this statistical nature, it is not a
surprise that the previous meta-analysis (i.e., Patterson et al.,
2008) examined the S1 amplitude and other investigators seek
other approaches, such as the difference between S1 and S2 am-
plitude, to better index sensory gating. Nonetheless, we suggest
that it is important to not ignore the relative contribution of the
S2 amplitude because the S2 amplitude is indispensable for the
ratio and difference scores.
The other major limitation is that this meta-analysis only
included 35 studies (58 comparisons). Due to a lack of report-
ing of either the S1 amplitude, S2 amplitude, and/or the P50 S2/
S1 ratio, many studies were not included in the present study,
and they may systematically differ from those studies included.
The analysis did not examine if the sensory gating deficit is
specific to schizophrenia patients as the P50 gating deficit has
also been reported in individuals with post-traumatic stress
disorder (e.g., Ghisolfi et al., 2004), panic disorder (e.g.,
Ghisolfi et al., 2006), bipolar disorder (e.g., Franks, Adler,
Waldo, Alpert, & Freedman, 1983; Sánchez-Morla et al., 2008)
and Alzheimer’s disease (Jessen et al., 2001). The sizes of these
bodies of literature are much smaller than that for schizophre-
nia. Therefore, it would be important to conduct other meta-
analyses that compare the magnitude of differences in the S1
amplitude, S2 amplitude, and P50 S2/S1 ratio between schizo-
phrenia patients and those psychiatric disorders when enough
data has accumulated.
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